Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNewcelX Ltd.

NewcelX Ltd.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.78 USD 0.06 ( 2.04%)
Last update at 2026-11-09T15:40:00Z
VOLUME
1525
Market Cap
19.18M

Momentum Score

…

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.43
Low
2.78
High
52 Week Price Range
1.83
Low
24.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.72
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.05
ROE
-
Net Debt
-1.85M
ROCE
-31.61%
Diluted EPS TTM
-2.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.30M -1.98M -12.17M -16.50M -11.95M
Net income -8.30M -1.98M -12.17M -16.50M -11.95M
Selling general administrative 1.35M 3.21M 5.90M 0.01M 0.01M
Selling and marketing expenses - - 0.09M 6.49M 5.93M
Gross profit - -0.00M -0.01M -0.01M -0.01M
Reconciled depreciation 0.06M 1.53M 2.29M 1.94M 1.85M
Ebit -2.29M -3.64M -11.81M -15.48M -11.86M
Ebitda -2.24M -3.63M -11.80M -15.47M -11.85M
Depreciation and amortization 0.06M 0.00M 0.01M 0.01M 0.01M
Operating income -2.47M -4.38M -11.81M -15.48M -11.86M
Other operating expenses 2.47M 4.38M 11.81M 15.48M 11.86M
Interest expense 6.01M 0.15M 0.15M 0.10M 0.07M
Tax provision - -0.03M -0.20M -0.17M -0.44M
Interest income 0.37M 0.02M 0.13M 0.05M 0.00M
Net interest income -5.74M -18.81M -1.14M -0.90M -2.41M
Income tax expense - -0.03M -0.20M -0.17M -0.44M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 2.47M 4.38M 11.81M 15.47M 11.85M
Cost of revenue - 0.00M 0.01M 0.01M 0.01M
Total other income expense net -5.83M 2.40M -0.36M -1.01M -0.09M
Net income from continuing ops -8.30M -26.55M -12.01M -22.72M -26.27M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.45M 2.23M 1.85M 9.28M 5.76M
Intangible assets 6.44M - - - -
Other current assets 0.98M 0.16M 0.91M 0.30M 0.29M
Total liab 4.20M 0.83M 10.68M 6.00M 5.22M
Total stockholder equity 7.25M 1.41M -8.83M 3.28M 0.54M
Other current liab 1.93M 0.45M 1.65M 0.99M 1.33M
Common stock 0.29M 0.17M 0.73M 0.67M 0.34M
Capital stock 0.29M 4.19M 4.19M 3.64M 3.37M
Retained earnings -84.89M -74.43M -70.37M -58.20M -41.71M
Good will 1.73M - - - -
Cash 2.20M 1.67M 0.90M 8.95M 5.43M
Total current liabilities 4.20M 0.83M 7.92M 3.36M 2.40M
Net debt -1.85M -1.67M 0.74M -8.95M -5.43M
Short term debt 0.35M - 1.63M - -
Short long term debt 0.35M 28.18M 8.65M 4.17M 4.22M
Short long term debt total 0.35M - 1.63M - -
Other stockholder equity 93.69M 72.82M 60.96M 60.86M 42.06M
Total current assets 3.18M 2.23M 1.82M 9.25M 5.72M
Net receivables - 0.40M 0.01M 0.04M 0.04M
Long term debt - - 0.83M 0.00M -
Inventory - - - -0.04M -0.04M
Accounts payable 1.92M 0.52M 4.63M 2.37M 1.74M
Accumulated other comprehensive income -1.84M 0.11M -0.16M -0.05M -0.15M
Non currrent assets other - 0.00M 0.02M 0.01M 0.01M
Non current assets total 8.26M 0.01M 0.02M 0.03M 0.04M
Capital lease obligations - - 1.31M 2.96M 1.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.60M 0.33M -0.66M -0.38M
Total cashflows from investing activities 1.70M -0.00M - -3.51M -0.04M
Net borrowings 0.29M 1.69M 4.51M 0.00M -2.00M
Total cash from financing activities 2.63M 5.04M 1.63M 17.40M 20.34M
Net income -8.30M -1.98M -12.17M -16.50M -11.95M
Change in cash 1.55M 0.77M -8.05M 3.52M 5.34M
Begin period cash flow 0.65M 0.90M 8.95M 5.43M 0.09M
End period cash flow 2.20M 1.67M 0.90M 8.95M 5.43M
Total cash from operating activities -2.77M -4.27M -9.68M -13.88M -14.94M
Issuance of capital stock 0.00M 0.00M 5.73M 5.47M 43.18M
Depreciation 0.06M 0.00M 0.01M 0.01M 0.01M
Other cashflows from investing activities - - 0.00M -3.51M -
Change to account receivables - - - - -0.02M
Other cashflows from financing activities - -0.21M - 7.35M 7.89M
Capital expenditures 0.01M 0.00M 0.00M 0.64M 0.04M
Change in working capital -1.07M 0.08M 2.25M 1.63M -3.17M
Stock based compensation 0.77M 0.13M 0.16M 0.02M 0.33M
Other non cash items 5.78M -2.49M 0.06M 0.34M 0.17M
Free cash flow -2.77M -4.27M -9.68M -13.88M -14.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NCEL
NewcelX Ltd.		 0.06
2.04%		 2.78 - - - 2.62 -0.29
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

NewcelX Ltd.

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.

Hohstrasse 1, Kloten, Switzerland, 8302

41 44 512 21 50

https://newcelx.com

9

Name Title Year Born
Mr. Ronen Twito CPA CEO & Executive Chairman 1975
Prof. Michel Revel M.D., Ph.D. Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director 1938
Mr. Omri Hagai Chief Financial Officer 1986
Mr. Alexander C. Zwyer M.B.A. Chief Business Officer & Executive Director 1969
Dr. Eric Konofal M.D., Ph.D. Head of Doxa Program 1967
Prof. Ariel Revel M.D. Director of Medical Affairs 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…